Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan R Goldfischer

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Urologic Clinics of North America|April 2, 2021
Clinical Research 2021Evan R Goldfischer
The Journal of Urology|February 11, 2003
Changes in urine volume accomplished by physicians treating nephrolithiasisJoan H Parks, Evan R Goldfischer, Frederic L Coe
Neurourology and Urodynamics|October 18, 2013
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled studyEvan R Goldfischer, Peter K Sand, Heather Thomas, et al.
The Journal of Urology|April 21, 2009
Assessing the impact of ureteral stent design on patient comfortJames E Lingeman, Glenn M Preminger, Evan R Goldfischer, et al.
The Journal of Sexual Medicine|July 12, 2013
A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapyEdward D Kim, Allen D Seftel, Evan R Goldfischer, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
Urology|April 15, 2014
Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunctionEvan R Goldfischer, Edward D Kim, Allen D Seftel, et al.
The Journal of Sexual Medicine|January 28, 2009
Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD)Anita H Clayton, Evan R Goldfischer, Irwin Goldstein, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|December 17, 2009
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomesSteven A Kaplan, Evan R Goldfischer, William D Steers, et al.
Advances in Therapy|December 29, 2016
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate CancerJürgen Breul, Eija Lundström, Daniela Purcea, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Urologic Clinics of North America|April 2, 2021
Clinical Research 2021Evan R Goldfischer
The Journal of Urology|February 11, 2003
Changes in urine volume accomplished by physicians treating nephrolithiasisJoan H Parks, Evan R Goldfischer, Frederic L Coe
Neurourology and Urodynamics|October 18, 2013
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled studyEvan R Goldfischer, Peter K Sand, Heather Thomas, et al.
The Journal of Urology|April 21, 2009
Assessing the impact of ureteral stent design on patient comfortJames E Lingeman, Glenn M Preminger, Evan R Goldfischer, et al.
The Journal of Sexual Medicine|July 12, 2013
A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapyEdward D Kim, Allen D Seftel, Evan R Goldfischer, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
Urology|April 15, 2014
Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunctionEvan R Goldfischer, Edward D Kim, Allen D Seftel, et al.
The Journal of Sexual Medicine|January 28, 2009
Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD)Anita H Clayton, Evan R Goldfischer, Irwin Goldstein, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|December 17, 2009
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomesSteven A Kaplan, Evan R Goldfischer, William D Steers, et al.
Advances in Therapy|December 29, 2016
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate CancerJürgen Breul, Eija Lundström, Daniela Purcea, et al.
Pageof 2